Plane WartsPhase 2NCT07710638
Efficacy of Ivermectin in the Treatment of Plane Warts
A Phase 2 study testing Ivermectin in people with Plane Warts, run by Al-Azhar University at 1 site in Egypt.
Trial summary
This study aims to evaluate the efficacy of ivermectin in the treatment of plane warts( flat warts). patients diagnosed with plane warts will be included to assess the clearance ratre of the lesions. Read more about this study
- Who is it for?
- Ages 5 years and older
- Conditions the study is for
- Plane Warts
- What is being tested?
- Ivermectin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2025to 1 Jul 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- • Patients with other types of warts (e.g., common, plantar, genital).
- History of hypersensitivity or allergy to ivermectin or its components.
- Patients who have received systemic immunosuppressive therapy within the last 3 months.
- Presence of chronic skin conditions that may interfere with evaluation (e.g., eczema, psoriasis).
- Patients with immunodeficiency disorders (e.g., HIV, organ transplant recipients).
- Pregnant or lactating females.
- Patients currently on systemic antiviral or immunomodulatory treatment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Randomized Controlled Clinical Trial to Evaluate the Efficacy of Oral and Topical Ivermectin in the Treatment of Plane Warts
This study aims to evaluate the efficacy of ivermectin in the treatment of plane warts( flat warts). patients diagnosed with plane warts will be included to assess the clearance ratre of the lesions.
- Conditions
- Plane Warts
- Being tested
- Ivermectin, Placebo
- Keywords
- ivermectin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IvermectinDrug
An antiparasitic medication evaluated for its immunomodulatory and antiviral efficacy in clearing plane warts. it will be administered to patients according to their assigned group protocol.
PlaceboOther
Patients in the control group will receive placebo,they will undergo standard clinical observation and follow up to monitor the natural course of the plane warts.
| Study group | Role | What they receive |
|---|---|---|
| Group1 : topical ivermectin | Experimental | Patients will receive topical ivermectin cream applied twice daily to plane warts for 3 months Receives: Drug: Ivermectin |
| Group 2 : oral ivermectin | Experimental | Patients will receive oral ivermectin once weekly for 3 months Receives: Drug: Ivermectin |
| control group 1 | Placebo comparator | Not described Receives: Other: Placebo |
| control group 2 | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
percentage of patients achieving complete clearance of plane warts
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start1 Jun 2025
- Primary completion1 Jul 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plane WartsStudies of the same condition, open and under way.
- More trials run by Al-Azhar UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Al-Azhar University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sarah Alfoully Ahmed, Al-Azhar University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07710638
- Sponsor's protocol ID
- AZHAR-DERM-2025-001
- Status last verified
- Oct 2026
- First submitted
- 14 Jul 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomized Controlled Clinical Trial to Evaluate the Efficacy of Oral and Topical Ivermectin in the Treatment of Plane Warts
- ClinicalTrials.gov ID
- NCT07710638
- Acronym / sponsor ID
- AZHAR-DERM-2025-001
- Conditions
- Plane Warts
- Keywords
- ivermectin
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Al-Azhar UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 Jul 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the efficacy of ivermectin in the treatment of plane warts( flat warts). patients diagnosed with plane warts will be included to assess the clearance ratre of the lesions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group1 : topical ivermectin | Experimental | Drug: IvermectinPatients will receive topical ivermectin cream applied twice daily to plane warts for 3 months |
| Group 2 : oral ivermectin | Experimental | Drug: IvermectinPatients will receive oral ivermectin once weekly for 3 months |
| control group 1 | Placebo comparator | Other: Placebo |
| control group 2 | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (7 listed)
- • Patients with other types of warts (e.g., common, plantar, genital).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IvermectinAn antiparasitic medication evaluated for its immunomodulatory and antiviral efficacy in clearing plane warts. it will be administered to patients according to their assigned group protocol. | Drug | Group 2 : oral ivermectin, Group1 : topical ivermectin |
| PlaceboPatients in the control group will receive placebo,they will undergo standard clinical observation and follow up to monitor the natural course of the plane warts. | Other | control group 1, control group 2 |
Primary outcome
percentage of patients achieving complete clearance of plane warts
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Plane Warts
RecruitingPhase 4
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
Common Wart, Flat Wart
RecruitingPhase 4
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
Viral Wart, Plantar Wart
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ivermectin in people with Plane Warts, run by Al-Azhar University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
percentage of patients achieving complete clearance of plane warts (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.